製品番号: HY-13593

クロラムブシル

(別名: Chlorambucil; CB-1348; WR-139013)

4 Cited Publications

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Chlorambucil (CB-1348), an orally active antineoplastic agent, is a CNS-penetrant bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.21%
CAS 番号: 305-03-3
分子式: C₁₄H₁₉Cl₂NO₂
分子量:304.21

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Chlorambucil 構造式

CAS 番号: 305-03-3

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (4)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

IC₅₀ & Target

DNA Alkylator^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	12500 nM Compound: Chl	Cytotoxicity against human 2008 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human 2008 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30996795]
4T1	IC₅₀	>100 μM Compound: Chlorambucil	Antiproliferative activity against mouse 4T1 cells after 72 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells after 72 hrs by MTT assay	[PMID: 28129978]
5637	IC₅₀	6.55 μM Compound: Chlorambucil	Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay	[PMID: 18434163]
5637	IC₅₀	6.55 μM Compound: Chlo	Cytotoxicity against human 5637 cells assessed as growth inhibition after 96 hrs by crystal violet staining assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 96 hrs by crystal violet staining assay	10.1039/C3MD00252G
786-0	IC₅₀	55.5 μM Compound: Chlorambucil	Anticancer activity against human 786-0 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay Anticancer activity against human 786-0 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28388522]
A 172	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human A172 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human A172 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
A 172	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human A172 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human A172 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
A2780	IC₅₀	52.5 μM Compound: chlorambucil	Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines	[PMID: 15027879]
A2780	IC₅₀	12 μM Compound: CLB	Antiproliferative activity against human A2780 cells after 72 hrs at 37 degC by MTT assay Antiproliferative activity against human A2780 cells after 72 hrs at 37 degC by MTT assay	10.1039/C6MD00271D
A2780cis	IC₅₀	43 μM Compound: CLB	Antiproliferative activity against human A2780cis cells after 72 hrs at 37 degC by MTT assay Antiproliferative activity against human A2780cis cells after 72 hrs at 37 degC by MTT assay	10.1039/C6MD00271D
A-375	IC₅₀	2.58 μM Compound: C5	Cytotoxicity against human A375 cells after 5 days by MTT assay Cytotoxicity against human A375 cells after 5 days by MTT assay	[PMID: 19121874]
A-375	CC₅₀	127 μM Compound: Chlorambucil	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 20615582]
A-375	IC₅₀	69.2 μM Compound: Chlorambucil	Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay	[PMID: 28818449]
A-375	IC₅₀	69.2 μM Compound: Chlorambucil	Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay	[PMID: 30108928]
A-427	IC₅₀	9.5 μM Compound: Chlorambucil	Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay	[PMID: 18434163]
A498	IC₅₀	280 μM Compound: Chlorambucil	Anticancer activity against human A498 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay Anticancer activity against human A498 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28388522]
A549	IC₅₀	43 μM Compound: 2, Chlorambucil, CLB	Cytotoxicity against human A549 cells by resazurin reduction test Cytotoxicity against human A549 cells by resazurin reduction test	[PMID: 18424156]
A549	GI₅₀	6.1 μM Compound: 1	Growth inhibition of human A549 cells expressing p53 after 7 days by celltiter-glo assay Growth inhibition of human A549 cells expressing p53 after 7 days by celltiter-glo assay	[PMID: 20973561]
A549	IC₅₀	85.7 nM Compound: Chlorambucil	Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
A549	IC₅₀	22.2 μM Compound: Chlorambucil	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 28818449]
A549	IC₅₀	43 μM Compound: CLB	Cytotoxicity against human A549 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test Cytotoxicity against human A549 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test	[PMID: 28927903]
A549	IC₅₀	18.8 μM Compound: Chlorambucil	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29649739]
A549	IC₅₀	22.2 μM Compound: Chlorambucil	Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay	[PMID: 30108928]
A549	IC₅₀	>50 μM Compound: Chlorambucil	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30243153]
A549	IC₅₀	72.78 μM Compound: Chlorambucil	Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay	[PMID: 31082763]
A549	IC₅₀	24.47 μM Compound: Chlorambucil	Growth inhibition of human A549 cells incubated for 5 days by SRB assay Growth inhibition of human A549 cells incubated for 5 days by SRB assay	[PMID: 32145644]
A549	IC₅₀	>40 μM Compound: CLB; 3d	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
A549	IC₅₀	21.09 μg/mL Compound: Chlorambucil	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
ACHN	IC₅₀	133 μM Compound: Chlorambucil	Anticancer activity against human ACHN cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay Anticancer activity against human ACHN cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28388522]
B16	IC₅₀	5.1 μM Compound: 1	In vitro cytotoxicity activity against B16 cells, by colony forming assay In vitro cytotoxicity activity against B16 cells, by colony forming assay	[PMID: 11985479]
B16	IC₅₀	220.3 μM Compound: chlorambucil	The compound was tested for inhibition of B16-BL6 melanoma cells growing in culture. The compound was tested for inhibition of B16-BL6 melanoma cells growing in culture.	[PMID: 1447731]
B16	IC₅₀	279.8 μM Compound: chlorambucil	The compound was tested for inhibition of B16-BL6 melanoma cells growing in culture with 0.25 mM DFMO. The compound was tested for inhibition of B16-BL6 melanoma cells growing in culture with 0.25 mM DFMO.	[PMID: 1447731]
B16	IC₅₀	>1000 nM Compound: 2; CLB	Antitumor activity against mouse B16 cells assessed as inhibition of cell viability incubated for 72 hrs by SRB assay Antitumor activity against mouse B16 cells assessed as inhibition of cell viability incubated for 72 hrs by SRB assay	[PMID: 38060985]
B16-F10	IC₅₀	12.59 μM Compound: Chlorambucil	Antiproliferative activity against mouse B16F10 cells incubated for 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells incubated for 72 hrs by MTT assay	[PMID: 31082763]
BALB/3T3	IC₅₀	69.72 μM Compound: Chlorambucil	Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay	[PMID: 31082763]
Bel-7402	IC₅₀	49.31 μM Compound: chlorambucil	Anticancer activity against human Bel7402 cells assessed as growth inhibition by MTT assay Anticancer activity against human Bel7402 cells assessed as growth inhibition by MTT assay	[PMID: 25050168]
Bel-7402	IC₅₀	49.31 μM Compound: chlorambucil	Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25050168]
Bel-7402	IC₅₀	>100 μM Compound: 12	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29407983]
Bel-7402	IC₅₀	>80 μM Compound: Chlorambucil	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29524728]
Bel-7402	IC₅₀	>50 μM Compound: Chlorambucil	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 30243153]
Bel7402/5-FU	IC₅₀	>100 μM Compound: 12	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 29407983]
Bel7402/5-FU	IC₅₀	>80 μM Compound: Chlorambucil	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 29524728]
BT-474	IC₅₀	237.5 μM Compound: 1	Cytotoxicity against human BT474 cells after 72 hrs by MTT assay Cytotoxicity against human BT474 cells after 72 hrs by MTT assay	[PMID: 24147900]
BT-474	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human BT474 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human BT474 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 29043812]
BT-474	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human BT-474 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 29126728]
BT-549	IC₅₀	>200 μM Compound: 1	Cytotoxicity against human BT549 cells after 72 hrs by MTT assay Cytotoxicity against human BT549 cells after 72 hrs by MTT assay	[PMID: 24147900]
BV-173	IC₅₀	34 μM Compound: Chlorambucil	In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
BXPC-3	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 24147900]
BXPC-3	IC₅₀	75300 nM Compound: Chl	Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30996795]
CAMA-1	IC₅₀	191.7 μM Compound: 1	Cytotoxicity against human CAMA1 cells after 72 hrs by MTT assay Cytotoxicity against human CAMA1 cells after 72 hrs by MTT assay	[PMID: 24147900]
CCRF-CEM	IC₅₀	21 μM Compound: Chlorambucil	In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
CCRF-CEM	IC₅₀	12.025 μM Compound: CLB; 3d	Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
CH1	IC₅₀	3.3 μM Compound: chlorambucil	Growth inhibition against CH-1 wild-type ovarian cell lines Growth inhibition against CH-1 wild-type ovarian cell lines	[PMID: 15027879]
CH1	IC₅₀	7.9 μM Compound: chlorambucil	Growth inhibition against CH-1 cisplatin resistant wild-type ovarian cell lines Growth inhibition against CH-1 cisplatin resistant wild-type ovarian cell lines	[PMID: 15027879]
CHO	IC₅₀	30 μM Compound: Chlorambucil	Dose required to inhibit cell growth was determined against CHO cell line Dose required to inhibit cell growth was determined against CHO cell line	[PMID: 11262080]
CHO	IC₅₀	84.5 μM Compound: CA, chlorambucil	Cytotoxicity against PAT active CHO cells after 48 hrs Cytotoxicity against PAT active CHO cells after 48 hrs	[PMID: 18281932]
CHO-AA8	IC₅₀	26 μM Compound: cholambucil	Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines. Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.	[PMID: 1992124]
CHO-AA8	IC₅₀	26 μM Compound: Chlorambucil	Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8 Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8	[PMID: 2033580]
CHO-AA8	IC₅₀	26 μM Compound: Chlorambucil	Cytotoxicity against AA8 cell line Cytotoxicity against AA8 cell line	[PMID: 2231599]
CHO-AA8	IC₅₀	26 μM Compound: 2 (chlorambucil)	Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8 Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8	[PMID: 2319563]
CHO-AA8	IC₅₀	36 nM Compound: Chlorambucil	Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours) Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)	[PMID: 2909741]
CHO-AA8	IC₅₀	38 μM Compound: 3	Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure) Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure)	[PMID: 7707327]
CHO-MG	IC₅₀	111.2 μM Compound: CA, chlorambucil	Cytotoxicity against PAT deficient CHO-MG cells after 48 hrs Cytotoxicity against PAT deficient CHO-MG cells after 48 hrs	[PMID: 18281932]
COLO 205	IC₅₀	18.8 μM Compound: Chlorambucil	Cytotoxicity against human COLO205 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human COLO205 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29649739]
COLO 205	IC₅₀	26.67 μg/mL Compound: Chlorambucil	Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
COS-7	IC₅₀	43.51 μM Compound: Chlorambucil	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
CT26	IC₅₀	>1000 nM Compound: 2; CLB	Antitumor activity against mouse CT26 cells assessed as inhibition of cell viability incubated for 72 hrs by SRB assay Antitumor activity against mouse CT26 cells assessed as inhibition of cell viability incubated for 72 hrs by SRB assay	[PMID: 38060985]
DAN-G	IC₅₀	27.8 μM Compound: Chlo	Cytotoxicity against human DAN-G cells assessed as growth inhibition after 96 hrs by crystal violet staining assay Cytotoxicity against human DAN-G cells assessed as growth inhibition after 96 hrs by crystal violet staining assay	10.1039/C3MD00252G
Daoy	IC₅₀	1.36 μM Compound: C5	Cytotoxicity against human DaOY cells after 5 days by MTT assay Cytotoxicity against human DaOY cells after 5 days by MTT assay	[PMID: 19121874]
DLD-1	IC₅₀	47 μM Compound: 2, Chlorambucil, CLB	Cytotoxicity against human DLD1 cells by resazurin reduction test Cytotoxicity against human DLD1 cells by resazurin reduction test	[PMID: 18424156]
DU-145	GI₅₀	9.4 μM Compound: 1	Growth inhibition of human DU145 cells after 7 days by celltiter-glo assay Growth inhibition of human DU145 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
DU-145	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 29043812]
DU-145	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 29126728]
Fibroblast	IC₅₀	99 μM Compound: 2, Chlorambucil, CLB	Cytotoxicity against human primary fibroblasts by resazurin reduction test Cytotoxicity against human primary fibroblasts by resazurin reduction test	[PMID: 18424156]
Fibroblast	IC₅₀	99 μM Compound: CLB	Cytotoxicity against human fibroblasts assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test Cytotoxicity against human fibroblasts assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test	[PMID: 28927903]
HCT-116	GI₅₀	105 μM Compound: Chlorambucil	Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line	[PMID: 11755363]
HCT-116	IC₅₀	57.6 μM Compound: Chlorambucil	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 28818449]
HCT-116	IC₅₀	>40 μM Compound: CLB; 3d	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
HCT-15	GI₅₀	8.1 μM Compound: 1	Growth inhibition of human HCT15 cells after 7 days by celltiter-glo assay Growth inhibition of human HCT15 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
HCT-15	IC₅₀	49700 nM Compound: Chl	Cytotoxicity against human HCT15 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30996795]
HCT-15	IC₅₀	3.11 μM Compound: Chlorambucil	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HEK293	IC₅₀	25 μM Compound: CLB	Antiproliferative activity against HEK293 cells after 72 hrs at 37 degC by CellTiter-Glo luminescence assay Antiproliferative activity against HEK293 cells after 72 hrs at 37 degC by CellTiter-Glo luminescence assay	10.1039/C6MD00271D
HeLa	IC₅₀	943 nM Compound: Chlorambucil	Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
Hep 3B2	GI₅₀	5.1 μM Compound: 1	Growth inhibition of human p53 deficient Hep3B cells after 7 days by celltiter-glo assay Growth inhibition of human p53 deficient Hep3B cells after 7 days by celltiter-glo assay	[PMID: 20973561]
HepG2	IC₅₀	111.8 μM Compound: Chlorambucil	Antiproliferative activity against human HepG2 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 72 hrs by CCK8 assay	[PMID: 28818449]
HepG2	IC₅₀	190 μM Compound: CLB	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 28818459]
HepG2	IC₅₀	>100 μM Compound: Chlorambucil	Antiproliferative activity against human HepG2 cells treated for 24 hrs measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells treated for 24 hrs measured after 72 hrs by MTT assay	[PMID: 29037951]
HepG2	IC₅₀	111.8 μM Compound: Chlorambucil	Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay	[PMID: 30108928]
HepG2/Adm	IC₅₀	297.1 μM Compound: CLB	Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 28818459]
HL-60	IC₅₀	38 μM Compound: Chlorambucil	In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
HL-60	IC₅₀	12.87 μM Compound: Chlorambucil	Antiproliferative activity against human HL60 cells treated for 24 hrs measured after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells treated for 24 hrs measured after 72 hrs by MTT assay	[PMID: 29037951]
HL-60	IC₅₀	11.63 μM Compound: 12	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29407983]
HL-60	IC₅₀	11.63 μM Compound: Chlorambucil	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29524728]
HL-60	IC₅₀	34.392 μM Compound: CLB; 3d	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
HL-60	IC₅₀	21.1 μM Compound: Chlorambucil	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition by MTT assay	[PMID: 37875056]
Hs-578T	IC₅₀	162 μM Compound: 1	Cytotoxicity against human Hs578T cells after 72 hrs by MTT assay Cytotoxicity against human Hs578T cells after 72 hrs by MTT assay	[PMID: 24147900]
HT-29	IC₅₀	>100 μM Compound: Chlorambucil	Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma	[PMID: 11262080]
HT-29	GI₅₀	129 μM Compound: Chlorambucil	Tested for in vitro concentration required to inhibit growth by 50% against HT-29 human colon cancer cell line Tested for in vitro concentration required to inhibit growth by 50% against HT-29 human colon cancer cell line	[PMID: 11755363]
HT-29	IC₅₀	70 μM Compound: 3	Cytotoxicity against human HT-29 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 19402667]
HT-29	GI₅₀	5 μM Compound: 1	Growth inhibition of human HT-29 cells after 7 days by celltiter-glo assay Growth inhibition of human HT-29 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
IMR-32	IC₅₀	18.8 μM Compound: Chlorambucil	Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29649739]
IMR-32	IC₅₀	20.09 μg/mL Compound: Chlorambucil	Cytotoxicity against human IMR32 cells after 72 hrs by MTT assay Cytotoxicity against human IMR32 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
JIMT-1	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human JIMT1 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human JIMT1 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 29043812]
JIMT-1	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human JIMT-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human JIMT-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 29126728]
K562	IC₅₀	11 μM Compound: Chlorambucil	Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia	[PMID: 11262080]
K562	IC₅₀	35 μM Compound: Chlorambucil	Cytotoxicity against K562 leukemia cells in vitro, expressed as the minimal concentration necessary to inhibit incorporation of [3H]thymidine by 50% Cytotoxicity against K562 leukemia cells in vitro, expressed as the minimal concentration necessary to inhibit incorporation of [3H]thymidine by 50%	[PMID: 12565950]
K562	IC₅₀	95 μM Compound: chlorambucil	Cytotoxicity against human leukemia cell line K562 Cytotoxicity against human leukemia cell line K562	[PMID: 15341486]
K562	IC₅₀	84 μM Compound: Chlorambucil	In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 24681986]
K562	IC₅₀	60.12 μM Compound: chlorambucil	Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25050168]
K562	IC₅₀	103 μM Compound: Chlorambucil	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
K562	IC₅₀	>100 μM Compound: CLB; 3d	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
KYSE-70 cell line	IC₅₀	38.4 μM Compound: Chlorambucil	Antiproliferative activity against human KYSE70 cells after 96 hrs by crystal violet assay Antiproliferative activity against human KYSE70 cells after 96 hrs by crystal violet assay	[PMID: 18434163]
L02	IC₅₀	105.78 μM Compound: chlorambucil	Cytotoxicity against human L02 cells by MTT assay Cytotoxicity against human L02 cells by MTT assay	[PMID: 25050168]
L02	IC₅₀	>600 μM Compound: CLB	Cytotoxicity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 28818459]
L02	IC₅₀	>100 μM Compound: 12	Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay	[PMID: 29407983]
L02	IC₅₀	>80 μM Compound: Chlorambucil	Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay	[PMID: 29524728]
L02	IC₅₀	>50 μM Compound: Chlorambucil	Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30243153]
L1210	IC₅₀	3 μM Compound: Chlorambucil	Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia	[PMID: 11262080]
L1210	IC₅₀	14.1 μM Compound: CA, chlorambucil	Cytotoxicity against mouse L1210 cells after 48 hrs Cytotoxicity against mouse L1210 cells after 48 hrs	[PMID: 18281932]
LCLC-103H cell line	IC₅₀	14.5 μM Compound: Chlo	Cytotoxicity against human LCLC-103H cells assessed as growth inhibition after 96 hrs by crystal violet staining assay Cytotoxicity against human LCLC-103H cells assessed as growth inhibition after 96 hrs by crystal violet staining assay	10.1039/C3MD00252G
LN-18	IC₅₀	>1000 nM Compound: 2; CLB	Antitumor activity against human LN-18 cells assessed as inhibition of cell viability incubated for 72 hrs by SRB assay Antitumor activity against human LN-18 cells assessed as inhibition of cell viability incubated for 72 hrs by SRB assay	[PMID: 38060985]
LNCaP	IC₅₀	124.3 μM Compound: Chlorambucil	Cytotoxicity against human LNCAP cells expressing androgen receptor after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells expressing androgen receptor after 72 hrs by MTT assay	[PMID: 23665800]
LoVo	IC₅₀	9 μM Compound: Chlorambucil	Dose to inhibit cell growth determined against LoVo cell line of human adenocarcinoma Dose to inhibit cell growth determined against LoVo cell line of human adenocarcinoma	[PMID: 11262080]
M4Beu cell line	IC₅₀	5.1 μM Compound: 1	In vitro cytotoxic activity against M4 Beu cells, by colony forming assay In vitro cytotoxic activity against M4 Beu cells, by colony forming assay	[PMID: 11985479]
M4Beu cell line	IC₅₀	>100 μM Compound: 2, Chlorambucil, CLB	Cytotoxicity against human M4Beu cells by resazurin reduction test Cytotoxicity against human M4Beu cells by resazurin reduction test	[PMID: 18424156]
M4Beu cell line	IC₅₀	>100 μM Compound: CLB	Cytotoxicity against human M4Beu assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test Cytotoxicity against human M4Beu assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test	[PMID: 28927903]
MCF7	GI₅₀	30 μM Compound: Chlorambucil	Tested for in vitro concentration required to inhibit growth by 50% against MCF-7 human breast cancer cell line cell line Tested for in vitro concentration required to inhibit growth by 50% against MCF-7 human breast cancer cell line cell line	[PMID: 11755363]
MCF7	IC₅₀	>100 μM Compound: 2, Chlorambucil, CLB	Cytotoxicity against human MCF7 cells by resazurin reduction test Cytotoxicity against human MCF7 cells by resazurin reduction test	[PMID: 18424156]
MCF7	IC₅₀	18.4 μM Compound: Chlorambucil	Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay	[PMID: 18434163]
MCF7	IC₅₀	4.5 μM Compound: C5	Cytotoxicity against human MCF7 cells expressing estrogen and progesterone receptor after 5 days by MTT assay Cytotoxicity against human MCF7 cells expressing estrogen and progesterone receptor after 5 days by MTT assay	[PMID: 19121874]
MCF7	GI₅₀	8.2 μM Compound: 1	Growth inhibition of human MCF7 cells after 7 days by celltiter-glo assay Growth inhibition of human MCF7 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
MCF7	IC₅₀	130.36 μM Compound: 3	Cytotoxicity against estrogen receptor-positive human MCF7 cells by MTT assay Cytotoxicity against estrogen receptor-positive human MCF7 cells by MTT assay	[PMID: 21051231]
MCF7	IC₅₀	73.3 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24147900]
MCF7	IC₅₀	56 μM Compound: Chlorambucil	Cytostatic activity against human MCF7 cells assessed as decrease in [3H]thymidine incorporation into DNA after 24 hrs by liquid scintillation counting analysis Cytostatic activity against human MCF7 cells assessed as decrease in [3H]thymidine incorporation into DNA after 24 hrs by liquid scintillation counting analysis	[PMID: 24681986]
MCF7	IC₅₀	97 μM Compound: Chlorambucil	In vitro antiproliferative activity against human MCF7 cells assessed as decrease cell viability after 24 hrs by MTT assay In vitro antiproliferative activity against human MCF7 cells assessed as decrease cell viability after 24 hrs by MTT assay	[PMID: 24681986]
MCF7	IC₅₀	52 μM Compound: Chlorambucil	Inhibition of collagen synthesis in human MCF7 cells assessed as 5-[3H]-proline incorporation into proteins susceptible to action of bacterial collagenase after 24 hrs Inhibition of collagen synthesis in human MCF7 cells assessed as 5-[3H]-proline incorporation into proteins susceptible to action of bacterial collagenase after 24 hrs	[PMID: 24713308]
MCF7	IC₅₀	56 μM Compound: Chlorambucil	Cytostatic activity against human MCF7 cells assessed as inhibition of DNA synthesis after 24 hrs by [3H]thymidine incorporation assay Cytostatic activity against human MCF7 cells assessed as inhibition of DNA synthesis after 24 hrs by [3H]thymidine incorporation assay	[PMID: 24713308]
MCF7	IC₅₀	97 μM Compound: Chlorambucil	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24713308]
MCF7	IC₅₀	80.54 μM Compound: chlorambucil	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25050168]
MCF7	IC₅₀	56 μM Compound: Chlorambucil	Inhibition of DNA synthesis in human MCF7 cells assessed as reduction in [3H]-thymidine incorporation incubated for 24 hrs by liquid scintillation counting method Inhibition of DNA synthesis in human MCF7 cells assessed as reduction in [3H]-thymidine incorporation incubated for 24 hrs by liquid scintillation counting method	[PMID: 25921266]
MCF7	IC₅₀	97 μM Compound: Chlorambucil	Cytotoxic activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxic activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 25921266]
MCF7	IC₅₀	26.4 nM Compound: Chlorambucil	Cytotoxicity against human MCF7 cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human MCF7 cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
MCF7	IC₅₀	97 μM Compound: Chlorambucil	Antiproliferative activity against human MCF7 cells assessed as cell viability pre-incubated for 24 hrs with CO2 followed by compound addition after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability pre-incubated for 24 hrs with CO2 followed by compound addition after 72 hrs by MTT assay	[PMID: 26680364]
MCF7	IC₅₀	>100 μM Compound: CLB	Cytotoxicity against human MCF7 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test Cytotoxicity against human MCF7 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test	[PMID: 28927903]
MCF7	IC₅₀	29.14 μM Compound: Chlorambucil	Antiproliferative activity in human MCF7 cells assessed as inhibition of cell proliferation Antiproliferative activity in human MCF7 cells assessed as inhibition of cell proliferation	[PMID: 29046238]
MCF7	IC₅₀	>50 μM Compound: Chlorambucil	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30243153]
MCF7	IC₅₀	69.33 μM Compound: Chlorambucil	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 31082763]
MCF7	IC₅₀	>100 μM Compound: Chlorambucil	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MCF7	IC₅₀	24.6 μM Compound: Chlorambucil	In vitro inhibitory activity against mammary carcinoma (MCF-7) cell line. In vitro inhibitory activity against mammary carcinoma (MCF-7) cell line.	[PMID: 9667961]
MCF7	IC₅₀	18.4 μM Compound: Chlo	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by crystal violet staining assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by crystal violet staining assay	10.1039/C3MD00252G
MCF7S	IC₅₀	1.7 μM Compound: 1	In vitro cytotoxic activity against MCF7, by colony forming assay In vitro cytotoxic activity against MCF7, by colony forming assay	[PMID: 11985479]
MDA-MB-231	IC₅₀	80 μM Compound: Chlorambucil	Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma	[PMID: 11262080]
MDA-MB-231	IC₅₀	>130 μM Compound: 2	Anticancer activity against human MDA-MB-231 cells assessed as cell survival after 72 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell survival after 72 hrs by MTT assay	[PMID: 20137939]
MDA-MB-231	IC₅₀	136.85 μM Compound: 3	Cytotoxicity against estrogen receptor-negative human MDA-MB-231 cells by MTT assay Cytotoxicity against estrogen receptor-negative human MDA-MB-231 cells by MTT assay	[PMID: 21051231]
MDA-MB-231	IC₅₀	>200 μM Compound: 1	Cytotoxicity against mitochondrial DNA-deficient human MDA-MB-231 rho theta-W02 cells after 72 hrs by MTT assay Cytotoxicity against mitochondrial DNA-deficient human MDA-MB-231 rho theta-W02 cells after 72 hrs by MTT assay	[PMID: 24147900]
MDA-MB-231	IC₅₀	>200 μM Compound: 1	Cytotoxicity against wild type human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against wild type human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24147900]
MDA-MB-231	IC₅₀	49 μM Compound: Chlorambucil	Cytostatic activity against human MDA-MB-231 cells assessed as decrease in [3H]thymidine incorporation into DNA after 24 hrs by liquid scintillation counting analysis Cytostatic activity against human MDA-MB-231 cells assessed as decrease in [3H]thymidine incorporation into DNA after 24 hrs by liquid scintillation counting analysis	[PMID: 24681986]
MDA-MB-231	IC₅₀	93 μM Compound: Chlorambucil	In vitro antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell vaibility after 24 hrs by MTT assay In vitro antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell vaibility after 24 hrs by MTT assay	[PMID: 24681986]
MDA-MB-231	IC₅₀	49 μM Compound: Chlorambucil	Cytostatic activity against human MDA-MB-231 cells assessed as inhibition of DNA synthesis after 24 hrs by [3H]thymidine incorporation assay Cytostatic activity against human MDA-MB-231 cells assessed as inhibition of DNA synthesis after 24 hrs by [3H]thymidine incorporation assay	[PMID: 24713308]
MDA-MB-231	IC₅₀	72 μM Compound: Chlorambucil	Inhibition of collagen synthesis in human MDA-MB-231 cells assessed as 5-[3H]-proline incorporation into proteins susceptible to action of bacterial collagenase after 24 hrs Inhibition of collagen synthesis in human MDA-MB-231 cells assessed as 5-[3H]-proline incorporation into proteins susceptible to action of bacterial collagenase after 24 hrs	[PMID: 24713308]
MDA-MB-231	IC₅₀	93 μM Compound: Chlorambucil	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24713308]
MDA-MB-231	IC₅₀	49 μM Compound: Chlorambucil	Inhibition of DNA synthesis in human MDA-MB-231 cells assessed as reduction in [3H]-thymidine incorporation incubated for 24 hrs by liquid scintillation counting method Inhibition of DNA synthesis in human MDA-MB-231 cells assessed as reduction in [3H]-thymidine incorporation incubated for 24 hrs by liquid scintillation counting method	[PMID: 25921266]
MDA-MB-231	IC₅₀	93 μM Compound: Chlorambucil	Cytotoxic activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 25921266]
MDA-MB-231	IC₅₀	520 nM Compound: Chlorambucil	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
MDA-MB-231	IC₅₀	>100 μM Compound: Chlorambucil	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28129978]
MDA-MB-231	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
MDA-MB-231	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
MDA-MB-231	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 29043812]
MDA-MB-231	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 29126728]
MDA-MB-231	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay	10.1039/C6MD00328A
MDA-MB-435	IC₅₀	>200 μM Compound: 1	Cytotoxicity against mitochondrial DNA-deficient human MDA-MB-435 rho theta-W01 cells after 72 hrs by MTT assay Cytotoxicity against mitochondrial DNA-deficient human MDA-MB-435 rho theta-W01 cells after 72 hrs by MTT assay	[PMID: 24147900]
MDA-MB-435	IC₅₀	>200 μM Compound: 1	Cytotoxicity against mitochondrial DNA-deficient human MDA-MB-435 rho theta-W02 cells after 72 hrs by MTT assay Cytotoxicity against mitochondrial DNA-deficient human MDA-MB-435 rho theta-W02 cells after 72 hrs by MTT assay	[PMID: 24147900]
MDA-MB-435	IC₅₀	150 μM Compound: 1	Cytotoxicity against wild type human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against wild type human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 24147900]
MDA-MB-436	IC₅₀	>160 μM Compound: 2	Anticancer activity against human MDA-MB-436 cells assessed as cell survival after 72 hrs by MTT assay Anticancer activity against human MDA-MB-436 cells assessed as cell survival after 72 hrs by MTT assay	[PMID: 20137939]
MDA-MB-436	IC₅₀	131.83 μM Compound: 3	Cytotoxicity against estrogen receptor-negative human MDA-MB-436 cells by MTT assay Cytotoxicity against estrogen receptor-negative human MDA-MB-436 cells by MTT assay	[PMID: 21051231]
MDA-MB-468	IC₅₀	0.65 μM Compound: C5	Cytotoxicity against human MDA-MB-468 cells expressing estrogen receptor after 5 days by MTT assay Cytotoxicity against human MDA-MB-468 cells expressing estrogen receptor after 5 days by MTT assay	[PMID: 19121874]
MDA-MB-468	IC₅₀	0.79 μM Compound: C5	Cytotoxicity against human MDA-MB-468 cells transfected with NAD(P)H: quinone oxidoreductase NQO1 after 5 days by MTT assay Cytotoxicity against human MDA-MB-468 cells transfected with NAD(P)H: quinone oxidoreductase NQO1 after 5 days by MTT assay	[PMID: 19121874]
MDA-MB-468	IC₅₀	146.88 μM Compound: 3	Cytotoxicity against estrogen receptor-negative human MDA-MB-468 cells by MTT assay Cytotoxicity against estrogen receptor-negative human MDA-MB-468 cells by MTT assay	[PMID: 21051231]
MDA-MB-468	IC₅₀	43.8 μM Compound: 1	Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTT assay	[PMID: 24147900]
MDA-MB-468	IC₅₀	67.5 μM Compound: 1	Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTT assay in presence of NAC Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTT assay in presence of NAC	[PMID: 24147900]
MDA-MB-468	IC₅₀	34.4 μM Compound: Chlorambucil	Anticancer activity against human MDA-MB-468 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay Anticancer activity against human MDA-MB-468 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28388522]
MDA-MB-468	IC₅₀	34.4 μM Compound: Chlorambucil	Growth inhibition of human MDA-MB-468 cells after 48 hrs by fluorescence polarisation assay Growth inhibition of human MDA-MB-468 cells after 48 hrs by fluorescence polarisation assay	[PMID: 30247905]
MDCK	IC₅₀	>100 μM Compound: Chlorambucil	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	>100 μM Compound: Chlorambucil	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	100 μM Compound: Chlorambucil	Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	93 μM Compound: Chlorambucil	Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	[PMID: 27823879]
MGC-803	IC₅₀	133.64 μM Compound: chlorambucil	Antiproliferative activity against human MGC803 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25050168]
MIA PaCa-2	IC₅₀	78.3 μM Compound: 1	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 24147900]
MIA PaCa-2	IC₅₀	>100 μM Compound: Chlorambucil	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 28129978]
MIA PaCa-2	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 29043812]
MIA PaCa-2	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 29126728]
MOLT-4	IC₅₀	6.3 μM Compound: Chlorambucil	In vitro inhibitory activity against acute lymphoblastic leukemia (MOLT4) cell line. In vitro inhibitory activity against acute lymphoblastic leukemia (MOLT4) cell line.	[PMID: 9667961]
MV4-11	IC₅₀	8.55 μM Compound: Chlorambucil	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay	[PMID: 31082763]
NCI/ADR-RES	GI₅₀	56 μM Compound: Chlorambucil	Tested for in vitro concentration required to inhibit growth by 50% against MCF-7/ADR human breast cancer cell line cell line Tested for in vitro concentration required to inhibit growth by 50% against MCF-7/ADR human breast cancer cell line cell line	[PMID: 11755363]
NCI-H1299	GI₅₀	4.9 μM Compound: 1	Growth inhibition of human p53 deficient H1299 cells after 7 days by celltiter-glo assay Growth inhibition of human p53 deficient H1299 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
NCI-H1299	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
NCI-H1299	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
NCI-H1299	IC₅₀	116.3 μM Compound: Chlorambucil	Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NCI-H1975	IC₅₀	28.16 μM Compound: Chlorambucil	Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay	[PMID: 32145644]
NCI-H460	IC₅₀	2.19 μM Compound: C5	Cytotoxicity against human H460 cells after 5 days by MTT assay Cytotoxicity against human H460 cells after 5 days by MTT assay	[PMID: 19121874]
NCI-H460	CC₅₀	104 μM Compound: Chlorambucil	Cytotoxicity against human H460 cells after 24 hrs by MTT assay Cytotoxicity against human H460 cells after 24 hrs by MTT assay	[PMID: 20615582]
NCI-H460	GI₅₀	11 μM Compound: 1	Growth inhibition of human NCI-H460 cells after 7 days by celltiter-glo assay Growth inhibition of human NCI-H460 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
NCI-H460	IC₅₀	28.9 μM Compound: Chlorambucil	Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay	[PMID: 30108928]
NIH3T3	IC₅₀	>600 μM Compound: CLB	Cytotoxicity against mouse NIH/3T3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 28818459]
P388	IC₅₀	7 μM Compound: Chlorambucil	Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia	[PMID: 11262080]
P388	IC₅₀	225 μM Compound: cholambucil	Optimal dose administered as a single dose by intraperitoneal inoculation of 10 X E6 murine leukemia P388 cell lines. Optimal dose administered as a single dose by intraperitoneal inoculation of 10 X E6 murine leukemia P388 cell lines.	[PMID: 1992124]
P388	IC₅₀	37 μM Compound: cholambucil	Percentage increase in lifespan of drug-related tumor bearing animals when heated at the optimal dose and tested in murine leukemia P388 cell lines. Percentage increase in lifespan of drug-related tumor bearing animals when heated at the optimal dose and tested in murine leukemia P388 cell lines.	[PMID: 1992124]
P388	IC₅₀	6.8 μM Compound: cholambucil	In vitro cytotoxicity against murine leukemia P388 cell line. In vitro cytotoxicity against murine leukemia P388 cell line.	[PMID: 1992124]
P388	IC₅₀	6.75 μM Compound: Chlorambucil	Inhibition of cell growth in culture against wild type P388 murine leukemia Inhibition of cell growth in culture against wild type P388 murine leukemia	[PMID: 2033580]
P388	IC₅₀	7.5 μM Compound: Chlorambucil	Cytotoxicity against P388 leukemia cell line Cytotoxicity against P388 leukemia cell line	[PMID: 2231599]
P388	IC₅₀	6.75 μM Compound: 2 (chlorambucil)	Tested for the in vitro cytotoxicity against P388 murine leukemia Tested for the in vitro cytotoxicity against P388 murine leukemia	[PMID: 2319563]
PA-1	IC₅₀	2.8 μM Compound: 2, Chlorambucil, CLB	Cytotoxicity against human PA1 cells by resazurin reduction test Cytotoxicity against human PA1 cells by resazurin reduction test	[PMID: 18424156]
PA-1	IC₅₀	2.8 μM Compound: CLB	Cytotoxicity against human PA1 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test Cytotoxicity against human PA1 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test	[PMID: 28927903]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	60 μM Compound: 53	Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay	[PMID: 29870668]
PBMC	IC₅₀	>200 μM Compound: Chlorambucil	Antiproliferative activity against human PBMC treated for 24 hrs measured after 72 hrs by MTT assay Antiproliferative activity against human PBMC treated for 24 hrs measured after 72 hrs by MTT assay	[PMID: 29037951]
PC-3	IC₅₀	131.3 μM Compound: Chlorambucil	Cytotoxicity against androgen receptor deficient human PC3 cells after 72 hrs by MTT assay Cytotoxicity against androgen receptor deficient human PC3 cells after 72 hrs by MTT assay	[PMID: 23665800]
PC-3	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human PC3 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human PC3 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
PC-3	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human PC3 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human PC3 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
PC-3	IC₅₀	>100 μM Compound: CLB	Cytotoxicity against human PC3 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test Cytotoxicity against human PC3 assessed as inhibition of cell growth incubated for 48 hrs by resazurin reduction test	[PMID: 28927903]
PC-3	IC₅₀	42.05 μM Compound: Chlorambucil	Antiproliferative activity against human PC3 cells treated for 24 hrs measured after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells treated for 24 hrs measured after 72 hrs by MTT assay	[PMID: 29037951]
PC-3	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by MTS assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by MTS assay	[PMID: 29043812]
PC-3	CC₅₀	>150 μM Compound: Chlorambucil	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 29126728]
PC-3	IC₅₀	40.35 μM Compound: 12	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29407983]
PC-3	IC₅₀	40.35 μM Compound: Chlorambucil	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29524728]
PC-3	IC₅₀	16.4 μM Compound: Chlorambucil	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
PC-9	IC₅₀	7.17 μM Compound: Chlorambucil	Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay	[PMID: 32145644]
Raji	IC₅₀	298 μM Compound: chlorambucil	In vitro cytotoxicity against Raji cells from human lymphoma In vitro cytotoxicity against Raji cells from human lymphoma	10.1016/0960-894X(94)80008-1
SF-268	GI₅₀	5.4 μM Compound: 1	Growth inhibition of human SF268 cells after 7 days by celltiter-glo assay Growth inhibition of human SF268 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
SH-SY5Y	IC₅₀	>40 μM Compound: CLB; 3d	Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
SK-BR-3	IC₅₀	247.5 μM Compound: 1	Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay	[PMID: 24147900]
SK-LU-1	IC₅₀	300 μM Compound: Chlorambucil	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
SK-OV-3	IC₅₀	35 μM Compound: chlorambucil	Growth inhibition against SKOV3 wild-type ovarian cell lines Growth inhibition against SKOV3 wild-type ovarian cell lines	[PMID: 15027879]
SK-OV-3	GI₅₀	5.5 μM Compound: 1	Growth inhibition of human SKOV3 cells after 7 days by celltiter-glo assay Growth inhibition of human SKOV3 cells after 7 days by celltiter-glo assay	[PMID: 20973561]
SMMC-7721	IC₅₀	163 μM Compound: Chlorambucil	Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay	[PMID: 30108928]
SN12C	IC₅₀	135 μM Compound: Chlorambucil	Anticancer activity against human SN12C cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay Anticancer activity against human SN12C cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28388522]
THP-1	IC₅₀	5.3 μM Compound: Chlorambucil	Antiproliferative activity against human THP1 cells treated for 24 hrs measured after 72 hrs by MTT assay Antiproliferative activity against human THP1 cells treated for 24 hrs measured after 72 hrs by MTT assay	[PMID: 29037951]
U-118-MG	IC₅₀	>40 μM Compound: CLB; 3d	Antiproliferative activity against human U-118-MG cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human U-118-MG cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
U-251	IC₅₀	33.11 μM Compound: Chlorambucil	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
U-87MG ATCC	IC₅₀	18.8 μM Compound: Chlorambucil	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29649739]
U-87MG ATCC	IC₅₀	18.82 μg/mL Compound: Chlorambucil	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
U-937	IC₅₀	37.7 μM Compound: Chlorambucil	Antiproliferative activity against human U-937 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human U-937 cells assessed as cell growth inhibition by MTT assay	[PMID: 37875056]
UO-31	IC₅₀	40.7 μM Compound: Chlorambucil	Anticancer activity against human UO-31 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay Anticancer activity against human UO-31 cells assessed inhibition of cell growth after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28388522]
UV4	IC₅₀	58 μM Compound: cholambucil	Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines	[PMID: 1992124]
UV4	IC₅₀	0.6 μM Compound: 2 (chlorambucil)	In vitro cytotoxicity against transformed chinese hamster fibroblast line UV4. In vitro cytotoxicity against transformed chinese hamster fibroblast line UV4.	[PMID: 2319563]
UV4	IC₅₀	1.2 μM Compound: 3	Growth inhibition activity was measured in repair deficient UV4 cells under aerobic conditions (4 hours drug exposure) Growth inhibition activity was measured in repair deficient UV4 cells under aerobic conditions (4 hours drug exposure)	[PMID: 7707327]
WiDr	IC₅₀	7.13 μM Compound: C5	Cytotoxicity against human WiDr cells after 5 days by MTT assay Cytotoxicity against human WiDr cells after 5 days by MTT assay	[PMID: 19121874]
WM 266-4	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human WM266.4 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human WM266.4 cells preincubated for 6 hrs cotreated with amonafide followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
WM 266-4	GI₅₀	>25 μM Compound: CLB	Growth inhibition of human WM266.4 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human WM266.4 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]

体外実験

Chlorambucil can deprive the function of complementary strands of DNA molecules via alkalization-induced cross interaction, and then inhibits tumor cell proliferation. Chlorambucil (0, 2.5, 5, 10 μM) exhibits slight inhibitory effect on Raji cell apoptosis, but potently increases DR4 and DR5 mRNA expression in Raji cells. Chlorambucil (10 μM) in combination with Tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL, 80 ng/ml) has synergistic effect on Raji cell apoptosis and inhibition on proliferation^[1].
Chlorambucil is a DNA alkylator at high doses and, at lower doses, acts as an inhibitor of synthesis of nuclear proteins, particularly histones. Increasing doses are associated with a higher frequency of apoptosis, whereas long-term maintenance therapy has been associated with mutations of the p53 gene, leading to secondary malignancies^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Chlorambucil (0.2 mg/kg, p.o.) in combination with levamisole (5 mg/kg) has enhanced anti-cancer effect on Ehrlich ascites carcinoma which elevates apoptosis of Ehrlich ascites carcinoma and the survival rate of the mice. However, Chlorambucil exhibits adverse effects on the liver and kidneys of mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 305-03-3
性状 Solid
分子量 304.21
分子式 C₁₄H₁₉Cl₂NO₂
Color White to yellow
SMILES

O=C(O)CCCC1=CC=C(N(CCCl)CCCl)C=C1
別名

Chlorambucil; CB-1348; WR-139013
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

J Autoimmun

Identification of Ribosomal Protein S4, Y-Linked 1 as a cyclosporin A plus corticosteroid resistance gene. [Abstract]

2020 Aug;112:102465. PMID: 32331925
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Clin Immunol

Identification of FCER1G as a cyclosporin A plus corticosteroid sensitization gene in female patients with Vogt-Koyanagi-Harada disease. [Abstract]

2023 Nov:256:109800. PMID: 37821074
Mol Biol Cell

Mitotic DNA damage promotes chromokinesin-mediated missegregation of polar chromosomes in cancer cells. [Abstract]

2023 May 1;34(5):ar47. PMID: 36989031

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (328.72 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2872 mL

16.4360 mL

32.8720 mL

5 mM

0.6574 mL

3.2872 mL

6.5744 mL

10 mM

0.3287 mL

1.6436 mL

3.2872 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[1]

Cultured cells at log-growth phase are digested by trypsin into single cell suspension and are seeded into 96-well plate at 1000 per well density. The plate is placed in a 37°C chamber with 5% CO₂. After attached growth for 24 h, cells are treated with TRAIL at 0, 20, 40 and 80 ng/mL or Chlorambucil at 0, 2.5, 5 and 10 μM for 48 h. 10 μL CCK-8 reagent is added to each well, followed by incubation at 37°C for 4 h. Absorbance values at 450 nm are then measured by a micro-plate reader. Six parallel samples are performed in each treatment group. Cell proliferation rate (%) = mean value of experimental group/mean value of control group × 100%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Female Swiss mice are divided randomly into five group (20 mice per group). Group 1 is kept as the control group, Group 2 receives intraperitoneal injection of by 2.5 × 10⁶ Ehrlich ascites carcinoma cell, Gropu 3 is treated orally with Chlorambucil 0.2 mg/kg body weight, Group 4 is treated orally with levamisole (5 mg/kg body weight) and Group 5 is treated orally with a combination of Chlorambucil and levamisole each day, using a bent stainless steel stomach tube^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Guo JX, et al. Synergistic effects of chlorambucil and TRAIL on apoptosis and proliferation of Raji cells. Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4703-4710. [Content Brief]

[2]. Salem FS, et al. Biochemical and pathological studies on the effects of levamisole and chlorambucil on Ehrlich ascites carcinoma-bearing mice. Vet Ital. 2011 Jan-Mar;47(1):89-95. [Content Brief]

[3]. Mohamed D, et al. Chlorambucil-adducts in DNA analyzed at the oligonucleotide level using HPLC-ESI MS. Chem Res Toxicol. 2009;22(8):1435-1446. [Content Brief]

[4]. Birnbaum AD, et al. Chlorambucil and malignancy. Ophthalmology. 2010;117(7):1466-1466.e1. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2872 mL	16.4360 mL	32.8720 mL	82.1801 mL
	5 mM	0.6574 mL	3.2872 mL	6.5744 mL	16.4360 mL
	10 mM	0.3287 mL	1.6436 mL	3.2872 mL	8.2180 mL
	15 mM	0.2191 mL	1.0957 mL	2.1915 mL	5.4787 mL
	20 mM	0.1644 mL	0.8218 mL	1.6436 mL	4.1090 mL
	25 mM	0.1315 mL	0.6574 mL	1.3149 mL	3.2872 mL
	30 mM	0.1096 mL	0.5479 mL	1.0957 mL	2.7393 mL
	40 mM	0.0822 mL	0.4109 mL	0.8218 mL	2.0545 mL
	50 mM	0.0657 mL	0.3287 mL	0.6574 mL	1.6436 mL
	60 mM	0.0548 mL	0.2739 mL	0.5479 mL	1.3697 mL
	80 mM	0.0411 mL	0.2055 mL	0.4109 mL	1.0273 mL
	100 mM	0.0329 mL	0.1644 mL	0.3287 mL	0.8218 mL

Chlorambucil

4 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

クロラムブシル

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Chlorambucil

生物活性

化学情報

Publications (4)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Chlorambucil 関連分類

製品番号: HY-13593